Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck

Shin, Dong M.; Glisson, Bonnie S.; Khuri, Fadlo R.; Lippman, Scott M.; Ginsberg, Lawrence E.; Diaz, Edward M.; Papadimitrakopoulou, Vassiliki A.; Feng, Lei; Francisco, Rhodette; Garden, Adam S.; Kies, Merrill S.; Myers, Jeffrey N.; Clayman, Gary L.; Hong, Waun Ki

doi:10.1002/cncr.10661

Cited by 52 publications

(28 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar to our results, Shin et al [25] reported a complete remission rate of 31% and a partial remission rate of 50%, with a local control rate of 81% and an overall survival at 1 and 2 years of 88 and 82%, respectively. Klug et al [26], representing 222 patients, reported an overall survival of 55% after 5 years and a local control probability of 74%.…”

Section: Discussionsupporting

confidence: 81%

“…Its effectiveness concerning locoregional tumor control and recurrence-free survival was shown [6] previously, as well as a good activity of the combination with paclitaxel/carboplatin [11,21,22,23,24]. This high effectiveness was confirmed by the initially published 1- and 3-year results of the presented study where the overall survival rate after 3 years was 84% [25]. At the same time, low toxicity, mainly mucositis but also dermatitis, thrombopenia and leukopenia could be managed with adequate supportive treatment.…”

Section: Discussionsupporting

confidence: 76%

See 1 more Smart Citation

Preoperative Paclitaxel/Carboplatin Radiochemotherapy for Stage III/IV Resectable Oral and Oropharyngeal Cancer: Seven-Year Follow-Up of a Phase II Trial

Eckardt

Sinikovic²,

Hofele³

et al. 2007

Oncology

View full text Add to dashboard Cite

Numerous treatment concepts for advanced but resectable oral and oropharyngeal squamous cell carcinoma exist. In this study, we present the 7-year results of a promising treatment with preoperative simultaneous chemoradiation using paclitaxel and carboplatin within a prospective phase II trial comprising 56 patients. After determination of the local tumor extension, chemoradiation was applied for 4 weeks and up to 40 Gy. Following a recovery period of 3–4 weeks, tumor resection was performed within the initially tattooed resection margins, together with a functional modified neck dissection. The median follow-up time was 44.9 ± 19.6 months (range 0.76–87.9). After 7 years, 35 (63.3%) patients were alive and 20 (36.4%) had died. In 2 patients (3.6%), the cause of death was related to treatment. After 7 years, the overall survival rate declined to 63.6%, whereas the local recurrence-free probability was still 84.2%. These results confirm the excellent local control and high survival rates of preoperative radiochemotherapy with the combination of paclitaxel/carboplatin.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionsupporting

confidence: 76%

Preoperative Paclitaxel/Carboplatin Radiochemotherapy for Stage III/IV Resectable Oral and Oropharyngeal Cancer: Seven-Year Follow-Up of a Phase II Trial

Eckardt

Sinikovic²,

Hofele³

et al. 2007

Oncology

View full text Add to dashboard Cite

show abstract

“…Thirty-five deaths occurred, 18 of which were from disease progression, six were treatment-related, two were from a second primary, and nine were from other medical causes, Argiris, Haraf, Kies et al 352 including toxicity. Although the induction chemotherapy with PFL-interferon was associated with considerable toxicity, its activity was comparable with newer taxane-based combination regimens, such as carboplatin, ifosfamide, and paclitaxel (TIC), cisplatin, 5-FU, leucovorin, and docetaxel (TPFL), and cisplatin, 5-FU, and docetaxel (TPF), that are currently under evaluation [36][37][38]. The reported survival rates with FHX were very promising, but locoregional control remained a major challenge.…”

Section: Induction Chemotherapy Followed By Fhxmentioning

confidence: 99%

Intensive Concurrent Chemoradiotherapy for Head and Neck Cancer with 5-Fluorouracil- and Hydroxyurea-Based Regimens: Reversing a Pattern of Failure

et al. 2003

Self Cite

View full text Add to dashboard Cite

Combined modality programs that were developed over the past two decades demonstrated that the nonsurgical therapy of locoregionally advanced head and neck cancer is feasible and produces survival outcomes that are at least comparable with surgery. The systemic therapy of head and neck cancer has gained momentum in recent years. Several randomized studies have shown that the concurrent administration of chemotherapy and radiation therapy is superior to radiation therapy alone. Medicine, 676 North St. Clair Street, Suite 850, Chicago, Illinois 60611, USA. Telephone: 312-695-6180; Fax: 312-695-6189; e-mail: aargiris@northwestern.edu Received December 10, 2002; accepted for publication April 21, 2003. ©AlphaMed Press 1083-7159/2003 The Oncologist ® LEARNING OBJECTIVESAfter completing this course, the reader will be able to:1. Discuss the results of multicenter trials with chemoradiotherapy with 5-FU-and hydroxyurea-based regimens for the treatment of locoregionally advanced head and neck cancer.2. Explain the rationale for the combination treatment of radiation, 5-FU, and hydroxyurea.3. Recognize the toxicities and potential functional impairment for patients treated with aggressive concurrent chemoradiotherapy.4. Discuss the experimental role of induction chemotherapy in the management of locoregionally advanced head and neck cancer.Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com CME CME This material is protected by U.S.

show abstract

“…A more aggressive, multiday regimen that added ifosfamide (TIC) has also been reported with considerable success in a phase II trial, but additional toxicity and a complicated therapy may outweigh marginally different response rates afforded by the addition of ifosfamide [11]. The use of carboplatin with paclitaxel takes advantage of the lower neurotoxicity of carboplatin compared with cisplatin and permits high-dose combinations and even weekly combination treatments with paclitaxel, which is neurotoxic.…”

Section: Introductionmentioning

confidence: 99%

Docetaxel, Cisplatin, 5-Fluorouracil (TPF)-Based Induction Chemotherapy for Head and Neck Cancer and the Case for Sequential, Combined-Modality Treatment

et al. 2003

View full text Add to dashboard Cite

Since the publication of the Veterans Affairs study in the early 1990s, much has been learned regarding the role of chemotherapy, radiation therapy, and more importantly, the role of combined-modality treatment with chemoradiation in the therapy of locally advanced head and neck cancer. There continues to be widespread variation and controversy in the timing, schedule, and intensity of chemotherapy and chemoradiation. Herein, we present the various approaches currently used in the year 2003 with a specific emphasis on the role of sequential combined-modality therapy combining chemotherapy, chemoradiotherapy, and surgery in the treatment of these malignancies.

show abstract

Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck

Abstract: BACKGROUND. This Phase II trial was conducted to determine the response rate,

Cited by 52 publications

References 35 publications

Preoperative Paclitaxel/Carboplatin Radiochemotherapy for Stage III/IV Resectable Oral and Oropharyngeal Cancer: Seven-Year Follow-Up of a Phase II Trial

Preoperative Paclitaxel/Carboplatin Radiochemotherapy for Stage III/IV Resectable Oral and Oropharyngeal Cancer: Seven-Year Follow-Up of a Phase II Trial

Intensive Concurrent Chemoradiotherapy for Head and Neck Cancer with 5-Fluorouracil- and Hydroxyurea-Based Regimens: Reversing a Pattern of Failure

Docetaxel, Cisplatin, 5-Fluorouracil (TPF)-Based Induction Chemotherapy for Head and Neck Cancer and the Case for Sequential, Combined-Modality Treatment

Contact Info

Product

Resources

About